M&A: Radiopharm Theranostics Ltd

Form Type: CORRESP

Filing Date: 2023-04-14

Corporate Action: Acquisition

Type: Update

Accession Number: 000121390023029665

Comments: Radiopharm Theranostics Limited is filing an amendment in response to comments from the U.S. Securities and Exchange Commission regarding their Registration Statement on Form 20-F. The company is concurrently filing Amendment No. 2 to address the comments received. Significant updates include the removal of product candidate RAD201 from the development pipeline due to lack of current plans for its development, along with the acquisition of Pharma15 through a stock purchase agreement, which includes post-closing contingent consideration of up to $3.2 million potentially payable in ordinary shares. The company has advised to disclose potential dilution impacts resulting from this issuance. Additionally, the company has made adjustments to its disclosure related to license maintenance fees and clarified arbitration provisions to eliminate inconsistencies. Overall, the document aims for compliance with SEC comments while providing important updates on the company's projects and acquisitions.

Document Link: View Document